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Abstract
Background: Regulatory T cells (Tregs) were shown to be central in maintaining immunological homeostasis and
preventing the development of autoimmune diseases. Several subsets of Tregs have been identified to date; however, the
dynamics of the interactions between these subsets, and their implications on their regulatory functions are yet to be
elucidated.
Methodology/Principal Findings: We employed a combination of mathematical modeling and frequent in vivo
measurements of several T cell subsets. Healthy BALB/c mice received a single injection of either hCDR1 - a tolerogenic
peptide previously shown to induce Tregs, a control peptide or vehicle alone, and were monitored for 16 days. During this
period, splenocytes from the treated mice were analyzed for the levels of CD4, CD25, CD8, CD28 and Foxp3. The collected
data were then fitted to mathematical models, in order to test competing hypotheses regarding the interactions between
the followed T cell subsets. In all 3 treatment groups, a significant, lasting, non-random perturbation of the immune system
could be observed. Our analysis predicted the emergence of functional CD4 Tregs based on inverse oscillations of the latter
and CD4
+CD25
2 cells. Furthermore, CD4 Tregs seemed to require a sufficiently high level of CD8 Tregs in order to become
functional, while conversion was unlikely to be their major source. Our results indicated in addition that Foxp3 is not a
sufficient marker for regulatory activity.
Conclusions/Significance: In this work, we unraveled the dynamics of the interplay between CD4, CD8 Tregs and effector T
cells, using, for the first time, a mathematical-mechanistic perspective in the analysis of Treg kinetics. Furthermore, the
results obtained from this interdisciplinary approach supported the notion that CD4 Tregs need to interact with CD8 Tregs
in order to become functional. Finally, we generated predictions regarding the time-dependent function of Tregs, which can
be further tested empirically in future work.
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Introduction
Regulatory T cells play an important role in both health and
disease,preventing the developmentofautoimmunityand regulating
the normalimmuneresponsetoinvading pathogens[1].Deficiencies
in such cells have been associated with several autoimmune diseases
[2], while their upregulation has been shown to be a key factor
mediating the beneficial effects of novel experimental treatments to
such diseases [3–5]. Several subsets of regulatory T cells have been
identified to date [6]; however, their developmental dynamics, as
well as the nature of interactions between them, are yet to be
characterized.
A peptide, hCDR1, that is based on the sequence of the
complementarity determining region (CDR)-1 of an autoantibody
[7], was shown to ameliorate the serological and clinical manifes-
tations of the autoimmune disease, systemic lupus erythematosus
(SLE) [8]. The beneficial effects of hCDR1, following tolerogenic
administrations,weredemonstratedtobemediatedviathe induction
of functional CD4
+CD25
+Foxp3
+ regulatory T cells (CD4 Tregs)
[4]. Furthermore, CD8
+CD28
2Foxp3
+ cells (CD8 Tregs) play an
important role in the ameliorative effects of hCDR1 as well, and
wereshown toberequired fortheoptimaldevelopment andfunction
of CD4 Tregs [9]. Moreover, a single injection of hCDR1 into
healthy, naı ¨ve mice was also shown to induce functional CD4
Tregs capable of suppressing the activity of effector T cells, as
demonstrated by the clinical improvement of SLE-afflicted mice
administered with these cells [4,9]. Thus, based on these results, it
was of interest to study the interactions between these different cell
subsets in healthy mice injected with hCDR1.
The application of mathematical models, in conjunction with
kinetically-measured experimental and clinical data, has proven in
the past to be an extremely useful approach, in particular in the
fields of virology and immunology [10–12]. In addition to
generally shedding light on the time-dependant behavior of the
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8447system at hand, such a methodology can produce both
quantitative and qualitative insights into the underlying mecha-
nisms [13,14]. The kinetics of regulatory T cells have been studied
in recent years [15–23]. However, this has not been yet done with
regard to a non-immunogenic (tolerogenic) immunomodulation by
a peptide. In addition, the interactions between different subsets of
regulatory T cells have not been previously studied kinetically.
While mathematical models have been applied to the investigation
of Tregs dynamics by Vukmanovic-Stejic et al., 2006, these models
were merely descriptive, and did not incorporate an explicit
specification of the biological interactions between different cell
populations.
The objective of the present work has been to quantitatively
characterize the time-dependent interplay between several im-
mune subpopulations, and in particular CD4
+CD25
2, CD4
+
CD25
+Foxp3
+ and CD8
+CD28
2Foxp3
+ cells, under tolerogenic
conditions. To this end, the kinetics of the latter cell subsets were
determined following a single subcutaneous injection of healthy
mice with hCDR1. By fitting the measured biological data to
mathematical models, the interactions between the 3 subpopula-
tions were analyzed.
Results
In Vivo Kinetics of Different Spleen-Derived T Cell Subsets
Healthy BALB/c mice were divided into 3 treatment groups,
receiving a single subcutaneous injection of either hCDR1, a
control (scrambled) peptide, or vehicle alone. At each time point
studied, 2 mice were sacrificed out of each treatment group, and
the percentage of spleen-derived cells bearing the markers CD4,
CD8, CD25, CD28 and Foxp3 was determined following staining
with the relevant antibodies, using flow cytometry. Figure 1
demonstrates the analysis performed on a representative day.
Substantial changes in the in vivo levels of the studied cell
populations were discernable over a period of 16 days following
either injection (Figure 2). In all 3 treatment groups, an initial
transient rise occurred in all cell subsets (with the exception of
CD4
+CD25
+Foxp3
2 cells) between days 0–4. Subsequently, the
observed kinetic patterns demonstrated statistically significant
cross-correlations between pairs of the different treatment groups
for most of the cell subsets (see details in Table S1). This implies
that the measured changes in cell populations did not represent
mere stochastic fluctuations but rather a genuine biological
process, since in the former case, the corresponding pairs of time
series would not be expected to be correlated across time.
Additional support for this statement is provided by the statistically
significant difference between the relatively small variance of
within-day measurements, as compared to the magnitude of
between-days changes (Figure 3; p-value,0.001 for all treatment
groups, Mann-Whitney U-test). Again, if the observed kinetics
represented solely random fluctuations, the variance of within-day
measurements and between-days changes would be expected to be
similar – as was indeed the case for untreated mice (i.e. mice that
were not injected with any substance) monitored over time. These
observations diminish the potential uncertainty in the results due
to the limited number of mice sacrificed each day in each
treatment group. It is noteworthy that the vehicle-only injection
produced kinetic patterns qualitatively similar to those obtained
following both other types of treatment.
Quantitatively, the most pronounced differences between the
kinetics induced by the 3 types of treatment were with regard to
the CD4 and CD8 Foxp3-expressing T cells (Figure 2E–F). More
specifically, these cells rose higher and earlier following the
administration of hCDR1, compared to the other types of
injections (days 7–11). Indeed, these cells have been previously
shown to mediate the beneficial therapeutic effects of hCDR1
[4,9]. The effect of hCDR1 was qualitatively reproduced in 3
independent experiments, with a total of N=136 mice analyzed.
As can be seen in Figure 2G, showing kinetic measurements of an
additional experiment, some quantitative differences may exist
between such repetitions; in particular, the exact timing of the rise
in the level of CD4
+CD25
+Foxp3
+ cells may slightly differ. In
untreated mice the level of CD4
+CD25
+Foxp3
+ remained more or
less constant over time (Fig 2H).
Throughout this work, we referred in our analysis to mea-
surements of cell percentages (out of total viable splenocytes, as
obtained by FACS measurements) rather than absolute numbers
of cells. This was done due to the additional noise introduced in
the latter as a result of differences in spleen sizes and cell numbers
between individual mice. Nonetheless, as exemplified in Figure S1,
compared to Figure 2E, we verified that absolute cell numbers
yielded qualitatively similar results to those reported here.
Correlation between the Kinetics of CD4
+CD25
2,
CD4
+CD25
+Foxp3
+ and CD8
+CD28
2Foxp3
+ Cells
In all 3 treatment groups, there was an apparent and persistent
growth in the population of CD4
+CD25
2 cells, with an overall
increase of 124%, 120%, and 131% in the level of these cells
following the hCDR1, control peptide, and vehicle injections,
respectively. After the initial response (days 0–4, see above), these
cells climbed gradually in an approximately exponential process
(i.e., linear on a logarithmic scale; see dotted line in Figure 4), with
similar doubling times in all 3 arms, equal to 26, 32, and 27 days.
Moreover, during the later stages of this process (days 9–16), the
CD4
+CD25
2 cells demonstrated fluctuations around the growth
trend line which were inversely correlated with the kinetics of
Foxp3-expressing CD4
+CD25
+ regulatory T cells; that is, a rise in
the regulatory T cells corresponded to a decrease in the growth
rate of CD4
+CD25
2 cells, and vice versa.
It is interesting to note that this inverse correlation was
observable only after the late rise of CD8
+CD28
2Foxp3
+ cells,
in days 7–8 (Figure 4). Indeed, as our data show, a minor increase
in the latter cells to a level lower than 1% corresponded to no
apparent consequent fluctuations of the CD4
+CD25
2 cells, as was
the case for the control peptide injection, compared with the other
two treatment groups (Figure 4).
Fitting the In Vivo Kinetics Using Mathematical Models
By fitting a mathematical model to the observed data, we were
able to show here that the hypothesis that CD4
+CD25
+Foxp3
+
cells modulate the proliferation rate of CD4
+CD25
2 cells after
interacting with CD8
+CD28
2Foxp3
+ cells matches well the
measured kinetics. More specifically, the mathematical model
used here represents 2 main biological assumptions: First, that
CD4
+CD25
+Foxp3
+ cells may expand independently (it should be
noted that it is known that regulatory T cells, although usually
anergic, may nonetheless expand in the proper milieu of
cytokines). Second, that a rise in these cells reduces the
proliferation rate of CD4
+CD25
2 cells and as a consequence
their level (and vice versa) – but only if the CD4
+CD25
+Foxp3
+
cells interacted first with CD8
+CD28
2Foxp3
+ cells. This last
assumption explains why in the control peptide treatment group,
unlike the 2 other treatment groups, the inverse fluctuations of the
CD4
+CD25
+Foxp3
+ and CD4
+CD25
2 populations were absent
since, as mentioned above, in this group only the level of
CD8
+CD28
2Foxp3
+ cells did not demonstrate a substantial and
persistent rise.
T Cell Subsets Dynamics
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the kinetics observed in days 4–16 (after the transient initial rise).
As can be seen, the predictions generated by the model agree well
with the measured levels of cells. Thus, we may conclude that the
suggested mechanism is not refuted by the available measurements
and explains them well.
We note that in the fitted mathematical model, it is assumed that
CD4
+CD25
2 cells respond to changes in the level of CD4
+
CD25
+Foxp3
+ cells, rather than to their absolute level itself. This
assumption is justified directly by the kinetic data: as can be seen in
Figure 4, for example for the hCDR1-injected group, the level of CD4
Tregs was generally lower between days 11–12, compared to their
level between days 14–16; nonetheless, the CD4
+CD25
2 subset
dropped between days 11 and 12, and rose between days 14 and
16. Thus, the absolute level of CD4 Tregs cannot be used to explain
the kinetics of CD4
+CD25
2 cells, unlike changes in this level. A
similar picture is evident with regard to the vehicle-only treatment
group. Accordingly, models which assume dependence between
CD4
+CD25
2dynamics and the absolute level of CD4
+CD25
+Foxp3
+
could not produce a good fit to the measured data.
Conversion Unlikely to Be the Sole Source of CD4 Tregs
The model described above assumes that the CD4
+CD25
+
Foxp3
+ population is capable of undergoing expansion, and that
Figure 1. Plot settings for analyzing CD4 and CD8 Tregs by flow cytometry. Percentages of CD4
+CD25
+Foxp3
+ cells (i.e. CD4 Tregs) and
CD8
+CD28
2Foxp3
+ cells in spleens from individual healthy BALB/c mice were determined at different time points over a period of 16 days following a
single subcutaneous injection of either a tolerogenic peptide (hCDR1), a control peptide or vehicle alone. Spleen-derived cells were triple-stained
with CD4, CD25 and Foxp3 and analyzed by flow cytometry. Shown are representative results obtained on day 9 following the injection. (A) The gate
of CD4
+ cells was subdivided for 6 regions corresponding to different intensities of staining with CD25. (B) The expression of Foxp3 was determined
in the different regions. Gray contours indicate staining with the isotype control. (C) Foxp3 relative expression in CD4
+ cells per intensity region of
CD25 staining. Accordingly, cutting borders that summate regions R4, R5, and R6 of CD25 intensity should properly indicate regulatory phenotype
based on Foxp3 staining.(A, B, C) present results with cells of mice injected with hCDR1 only. (D) Representative dot plots of CD4 and CD25-
expressing spleen-derived cells and histograms of Foxp3 expression in the CD4
+CD25
+ cells from the 3 treatment groups. (E) Representative dot plots
of CD8 and CD28-expressing spleen-derived cells and histograms of Foxp3 expression in the CD8
+CD28
2 cells from the 3 treatment groups.
doi:10.1371/journal.pone.0008447.g001
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PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8447Figure 2. The kinetics of spleen-derived T cell subsets. Healthy BALB/c mice received a single injection of one of three alternative treatments
(hCDR1, vehicle-only, control peptide). In each inspected day, 2 mice were sacrificed out of each treatment group, and the percentage of cells bearing
the markers CD4, CD8, CD25, CD28 and Foxp3 was determined using flow cytometry. Points represent measured values, lines connect the daily
averages. Presented cell subpopulations: (A) CD4
+CD25
2 (B) CD8
+CD28
+ (C) CD4
+CD25
+Foxp3
2 (D) CD8
+CD28
2Foxp3
2 (E) CD4
+CD25
+Foxp3
+ (F)
CD8
+CD28
2Foxp3
+. Panel (G) compares the kinetics of CD4
+CD25
+Foxp3
+ cells in two different experiments, following injection of hCDR1. Panel (H)
presents measurements of CD4
+CD25
+Foxp3
+ cells, taken from mice which received no injection, as compared to mice injected with vehicle alone.
Note that both in panel (G) and panel (H), the reported data are absolute shifts from the baseline (i.e. day 0 measurements), to enable comparison
over different experiments.
doi:10.1371/journal.pone.0008447.g002
T Cell Subsets Dynamics
PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8447this process constitutes the main source for its increase, rather than
conversion of CD4
+CD25
2 and/or CD4
+CD25
+Foxp3
2 cells.
While this assumption yields a good fit to the data for all 3
treatment groups, we cannot rule out the possibility that
conversion is the major contributor to the late rise (days 11–14)
of CD4 Tregs cells in two of the treatment groups – the mice
injected with hCDR1, and those injected with vehicle-alone.
However, in the third group – the control peptide-injected mice –
conversion cannot play such a role, as in this arm the substantial
rise of the CD4
+CD25
+Foxp3
+ population between days 11 and
14 is not accompanied by a concurrent decrease in the
CD4
+CD25
2 and CD4
+CD25
+Foxp3
2 subsets.
Discussion
In this work we have combined, for the first time, mathematical
modeling with frequent in vivo sampling, in order to characterize
the processes responsible for the development of regulatory T cells
in response to the tolerogenic administration of a peptide. The
results obtained taking this approach predicted the emergence of
functional CD4 Tregs based on the occurrence of inverse
oscillations of the latter and CD4
+CD25
2 cells. Furthermore, we
demonstrated that at least in the studied system, CD4 Tregs
require a sufficiently high level of CD8 Tregs in order to become
functional. In addition, our analysis implied that conversion of
effector cells is not the major source of CD4 Tregs here.
The beneficial effect of hCDR1 was previously shown to be
mediated by the upregulation of a specific population of CD4
Tregs [4]. Accordingly, we have shown here that the administra-
tion of this peptide induced a significant, lasting (over two weeks),
non-random perturbation of the immune system. Following an
initial, transient rise of all of the studied immune populations
(which may be interpreted as a response to the injection itself), a
significant expansion of CD8
+CD28
2Foxp3
+ cells preceded the
occurrence of inverse oscillations of CD4
+CD25
+Foxp3
+ and
CD4
+CD25
2 cells, such that a rise in the former subset was
accompanied by a fall in the latter and vice versa. This kinetic
behavior matches the previously reported capability of hCDR1-
induced CD4 Tregs to suppress the proliferation of CD4 effector
cells [4], and its dependency on the presence of CD8 Tregs [9].
Moreover, when these hypothesized interrelations between the
above 3 cell populations were represented mathematically, the
predictions generated by the resulting model fitted well the cell
levels measured over time, showing that the suggested mechanism
can indeed explain the actual data.
Similar kinetic patterns, albeit with lower magnitudes, were
observed in mice injected with vehicle alone, including the above-
mentioned inverse oscillations; this suggests functional suppression
by CD4 Tregs in these mice as well. However, CD4 Tregs taken
from vehicle treated mice are known to be ineffective in
suppressing autoreactive T cells in SLE-afflicted mice [4]. One
possible explanation for this alleged discrepancy may lie in the
specificities of the upregulated T cells in each case: while the
administration of hCDR1 induces the expansion of cells with
specificities relevant to the SLE-context, the cells responding to the
injection of the vehicle alone probably represent a plethora of
Figure 3. A comparison of the within-day and between-days variations for the different groups. The within-day variation was computed
as the difference between each FACS measurement and its corresponding daily average (i.e. the average of the 2 measurements taken for the
relevant day, cell subset and treatment group), divided by this average. The between-days variation was computed as the difference between each
daily average and the overall average of the series (i.e., the average of all the measurements related to a cell subset and treatment group), divided by
the overall average. The division by averages serves as a normalization step, allowing to compare all cell subsets together. Horizontal lines represent
the medians. The statistical significance of the differences between the within-day and between-days variations was estimated using the non-
parametric Mann-Whitney U-test, resulting with P,0.001 for each of the 3 treatment groups. For the non-injected mice, the difference between the
within-day and between-days variations was not statistically significant.
doi:10.1371/journal.pone.0008447.g003
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latter will be non-functional in SLE-afflicted mice, within the
healthy injected mice we can still expect suppression of CD4
effector cells by CD4 Tregs. The induction of a significant
perturbation to the immune system by the injection of a vehicle
may be a result of a ‘‘danger signal’’ provided by the injection
itself. Thus, the effect observed in the vehicle-treated group may
represent an example of a normal regulation of the immune
system, which involves not only effector T cells but also Tregs to
secure proper balance of the quality and magnitude of the
response [24].
It has been previously shown [4] that the injection of the control
peptide does not yield functional CD4 Tregs. Indeed, as shown
here, in the mice treated with this peptide no inverse oscillations of
CD4
+CD25
2 and CD4
+CD25
+Foxp3
+ cells were recorded. This
can be explained by our observation that in this group the
CD8
+CD28
2Foxp3
+ cells did not rise to the same level as in the
other two treatment groups, and started declining earlier. It should
be noted that while the control peptide binds MHC class II with
the same avidity as hCDR1, the injection of the two peptides
results nevertheless in different immunological effects. Thus,
whereas hCDR1 was shown to down-regulate the production of
IFN-c and to up-regulate TGF-b, the control peptide did not
inhibit and sometimes rather led to increased production of IFN-c
and did not affect the expression of TGF-b [25]. These differences
could partially explain the inability of the control peptide to
Figure 4. The correlated kinetics of CD4
+CD25
2, CD4
+CD25
+Foxp3
+ and CD8
+CD28
2Foxp3
+ cells, for each of the treatment groups.
The levels of CD4
+CD25
2 (red) cells are specified on the left y-axis, those of CD4
+CD25
+Foxp3
+ (orange) and CD8
+CD28
2Foxp3
+ (blue) cells on the
right y-axis. Points represent the values measured by FACS, lines connect daily averages. Note the logarithmic scale of both y-axes. Following an initial
transient response in all 3 subsets (days 0–4; days 0–6 for the additional experiment involving the hCDR1 treatment), the CD4
+CD25
2 population
grew in an approximately exponential process (dotted line; log-linear regression was calculated based on the measurements taken in the days
following the initial response, i.e. disregarding the shaded areas). In the second part of the experiment (day 9 on) fluctuations of CD4
+CD25
2 cells
around the regression line were inversely correlated with changes in CD4
+CD25
+Foxp3
+ cell levels – but only in the hCDR1 and vehicle-only
treatment groups, where CD8
+CD28
2Foxp3
+ cells rose and persistently stayed above a hypothetical threshold (dashed line).
doi:10.1371/journal.pone.0008447.g004
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development of functional CD4 Tregs.
The above observations suggest that the administration of
hCDR1 and, to a lesser degree, of vehicle alone, promote a
transition to a ‘‘regulatory regime’’, involving a rise in both CD4
and CD8 Treg populations, a suppression of CD4 effector cells
and, possibly, the conversion of such cells into CD4 Tregs. The
administration of the control peptide seems not be sufficient to
trigger such a transition. Thus, the rise of CD8 Tregs is, in this
case, less significant and transient, and the resulting CD4 Tregs
are non-functional. Accordingly, fitting the observed kinetics with
mathematical models showed that while in mice injected with
hCDR1 or vehicle alone the late rise of CD4 Tregs may be
explained (at least in part) by conversion of CD4 effector cell, this
is not the case for the control peptide treatment group. However,
the similarity in the kinetic profiles of CD4 Tregs in all 3 arms may
imply that conversion is not the sole source of CD4 Tregs also in
the other two treatment groups.
Although an increase of CD4
+CD25
+Foxp3
+ cells was observed
following the administration of the control peptide, these cells did
not suppress the proliferation of CD4
+CD25
2 cells; this suggests
that Foxp3 is not a sufficient marker for a regulatory phenotype, as
was previously discussed [26]. Indeed, additional molecules such
as TGF-b, CTLA-4, and Bcl-xL were shown to play a key role in
the development of hCDR1-induced functional Tregs [4,9,27].
In previous studies, hCDR1 was administered in the context of
SLE, namely, it was injected either to SLE-afflicted mice [8],
young, SLE-prone mice [4], or mice that were immunized with an
SLE-inducing anti-DNA antibody that bears a major idiotype,
16/6Id [9,28]. The injection of the tolerogenic peptide induced
CD8 and CD4 Tregs in the treated mice [4,9]. In this study,
however, we analyzed the development of the two subsets of Tregs
Figure 5. Fitting a mathematical model to the measured data. The plotted solid curves were generated using a mathematical model (see
Materials and Methods for details), fitting the measured levels of CD4
+CD25
2 (red, left y-axis) and CD4
+CD25
+Foxp3
+ (orange, right y-axis) cells in
days 4–16 (days 6–14 for the additional experiment involving the hCDR1 treatment). The approximated levels of CD8
+CD28
2Foxp3
+ cells (blue,
dashed line, right y-axis) were not produced by the model, but were rather interpolated from the actual measurements and used as an input to the
model. Points represent the daily averages of the values measured by FACS. Note the logarithmic scale of both y-axes.
doi:10.1371/journal.pone.0008447.g005
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injection of this tolerogenic peptide during a 16-day follow-up
period. The cell status in the disease-free context as compared with
that in SLE-afflicted mice is significantly different in regard
to their degree of activation, the level of apoptosis, and the
production of pathogenic cytokines. Hence, the use of naı ¨ve mice
enabled us to compare the effects of hCDR1 and a control peptide
on the induction of CD8 and CD4 Tregs without the background
of general activation of the cells.
The model used here assumes that CD4
+CD25
2 cells respond
to changes in the levels of CD4 Tregs, rather than to their absolute
numbers; assuming the latter failed to produce a good fit to
the data since in different time intervals, comparable levels of
CD4 Tregs were accompanied by either a rise or a drop in
CD4
+CD25
2 cells. One can avoid the reliance on changes
(represented mathematically by the time-derivative) by associating
the suppression of CD4
+CD25
2 cells with a signal (e.g. a cytokine)
having the following properties (see Text S1): it stimulates its own
production (i.e. participates in a positive feedback loop), it is
consumed by CD4
+CD25
+Foxp3
+ cells, and may serve as a
growth factor for them. Although the predicted cytokine may be
initially secreted by the Tregs, they are not likely to be its major
producers. TGF-b is a possible candidate to serve as this signal, as
it answers the above description [4,28,29]. It should be noted that
while even without these modifications the model may be
considered too complicated given the amount of available data,
simpler or comparably complicated alternative models tested by us
(see Text S1) failed to explain the observed kinetics.
The combination of mathematical models and in vivo kinetic
measurements utilized in the current work has allowed us to gain
new insights into the mechanisms governing the function of
regulatory T cells, and to generate predictions that can be further
tested in future work.
Materials and Methods
Ethics Statement
The study has been approved by the Animal Care and Use
committee of the Weizmann Institute of Science.
Mice
Female BALB/c mice were purchased from Harlan (Jerusalem,
Israel).
Synthetic Peptides
A peptide with the following sequence GYYWSWIRQPPGK-
GEEWIG (hCDR1) based on the CDR1 of the human anti-DNA
monoclonal antibody [30] bearing the 16/6Id was synthesized by
Polypeptide laboratories (LA, USA) and used in this study. A
peptide with scrambled order of the amino acids of the hCDR1,
SKGIPQYGGWPWEGWRYEI (‘scrambled peptide’) was syn-
thesized and used as a control. The control peptide binds MHC
class II with an avidity similar to that of hCDR1.
Treatment of Mice
Mice at the age of 2 months were divided into 3 groups (N=24
mice for the hCDR1-injected group, N=18 for the other two
groups) and treated with a single subcutaneous injection of either
hCDR1 (50 mg/mouse) or the control (scrambled) peptide (50 mg/
mouse) that were administered in the vehicle CaptisolH (Sulfobu-
tylether beta cyclodextrin that has been designed by CyDex to
enhance the solubility and stability of drugs). A third group of mice
was treated with a single subcutaneous injection of the vehicle
only.
mAbs
The following Abs were used for immunofluorescent staining of
cells: Anti-CD4-PE (clone GK1.5), anti-CD4-APC (clone L3T4),
anti-CD25-FITC (clone 7D4), anti-CD8-FITC (clone 53-6.7), and
their matched isotype controls were obtained from Southern
Biotechnology Associates (Birmingham, AL). Anti-CD28-PE
(clone 37.51), and its matched isotype controls were purchased
from PharMingen (San Diego, CA, USA). Anti-Foxp3-FITC
(clone FJK-16s Set) was purchased from eBioscience (San Diego,
CA).
FACS Analysis
Cells were incubated with the relevant Ab and analyzed by
FACS (Becton Dickinson, Franklin Lakes, NY). For intracellular
staining, the cells were incubated with a fixation solution, washed,
and resuspended in permeabilization solution (Serotec; Oxford,
UK).
Kinetic Analysis
Thepercentagesofthe6 differentcellpopulations (CD4
+CD25
2,
CD4
+CD25
+Foxp3
2, CD4
+CD25
+Foxp3
+, CD8
+CD28
+, CD8
+
CD28
2Foxp3
2, CD8
+CD28
2Foxp3
+) out of total viable spleno-
cytes, as obtained from FACS measurements, were used for the
analysis of kinetics and fitting by mathematical models. Measure-
ments were taken on days 0, 2, 3, 4, 5, 7, 8, 9, 11, 12, 14 and 16
followinginjection for the micetreatedwith hCDR1, and on days 0,
2, 3, 4, 7, 8, 9, 11, 14 and 16 following injection for the two other
treatment groups. Cell subset percentages, rather than absolute cell
numbers, were used in the analysis, due to the additional noise
detected in the latter due to differences in spleen sizes and cell
numbers between individual mice.
Mathematical Models
ODE-based mathematical models were used to fit the levels of
CD4
+CD25
2 cells (T4E) and CD4
+CD25
+Foxp3
+ cells, which
were assumed to be either non-functional (T4R) or functional (T 
4R).
The dynamics of CD8
+CD28
2Foxp3
+ cells (T8R) were not
modeled here, but were rather interpolated from the data and
used as an input to the models. We assumed that cell dynamics in
the first few days following the s.c. injection represented a transient
response to it. Thus, our models, describing the suppressive effect
of Tregs, focused on the dynamics during the second part of the
experiment period.
Several different models were tested (see Text S1), but only one
model, described next, yielded a fit that was able to describe the
entire observed kinetic pattern:
dSdngr
dt
~{adngrSdngr ð1Þ
dT4R
dt
~{ d4RT4R{kregT4RT8R
   h
n
dngr
h
n
dngrzSn
dngr
ð2Þ
dT 
4R
dt
~ kregT4RT8Rz
tn
reg
tn
regztn p4R{d4R
 !
T 
4R
"#
h
n
dngr
h
n
dngrzSn
dngr
ð3Þ
dT4E
dt
~ p4E{kmod
dT 
4R
dt
Tn
8R
h
n
8RzTn
8R
  
T4E{d4ET4E ð4Þ
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PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8447In this model, Sdngr represents a ‘‘danger signal’’, induced by the
initial subcutaneous injection; it is assumed, in the absence of an
actual immunogenic signal, that Sdngr decays exponentially with rate
constantadngr.Initially,T 
4R~0.Aslongasthedangersignalislarger
thanacertainthresholdhdngr,thepopulationofCD4
+CD25
+Foxp3
+
cells remains stable and nonfunctional with an initial level
T4R =TInit
4R .Oncethedangersignaldecaysbelowhdngr andfollowing
a necessary interaction with CD8
+CD28
2Foxp3
+ cells, T4R cells
start differentiating into functional CD4 Tregs with probability kreg
per T4R-T8R-interaction. Both functional and nonfunctional CD4
Tregs are removed from the system with rate d4R. It is assumed that
nonfunctional Tregs do not significantly expand, while functional
Tregs expand with rate p4R, as long as the time since injection does
not exceed a certain threshold treg. The basic proliferation rate
constant of CD4
+CD25
2 cells (T4E)i sp4E, and it is modulated by
changesinthe leveloffunctionalCD4 Tregs witha factor kmod.Th is
processalso requires that the levelofCD8
+CD28
2Foxp3
+(T8R)c e l l s
is above a certain threshold, h8R.C D 4
+CD25
2 cells are assumed to
be removed from the system with rate d4E. n is assumed to be an
exponent large enough to produce effective step-functions.
Note that since measurements of the danger signal are not
available, we replaced the dependency on this signal (i.e. the Hill
functions in Eqs. 2 & 3) by a step function dependent on time.
Furthermore, a possible biological explanation for the dependency
on the time derivative of T 
4R appearing in Eq. 4 is a signal, e.g.
cytokine, that is strongly affected by changes in the T 
4R population
(see a detailed description of an explicit model with such signal in
Text S1). Note also that we do not necessarily assume that all of
the CD4
+CD25
2 cells respond to the interactions with the
functional CD4 Tregs; it is possible to split the population of
CD4
+CD25
2 cells into ‘‘responding’’ and ‘‘non-responding’’
(static) cells, without affecting the quality of the resulting fit.
Nonlinear Fitting
Mathematical models were fitted to the experimental data using
Berkeley Madonna (University of California, Berkeley, CA). Due
to the exploratory nature of this study, hence a limited amount of
collected data, the goal of fitting here was to assess the plausibility
of qualitatively different models, rather than to estimate the values
of parameters. Daily averages (2 mice each day) were fitted rather
than individual measurements. The kinetics of the first 4 days of
each experiment (6 days for the additional hCDR1 experiment)
were not fitted, due to the assumptions described above.
Statistical Analysis
Within-day variation was estimated by the difference between
each measurement and its corresponding daily average, divided by
the average. Between-days variation was estimated by considering
the differences between daily averages and the corresponding
average over time, divided by the latter. The above normalization
step was used in order to allow the comparison of all cell subsets
together. The two samples of relative differences were then
compared using the non-parametric Mann-Whitney U-test.
Supporting Information
Text S1 Additional mathematical models.
Found at: doi:10.1371/journal.pone.0008447.s001 (0.09 MB
DOC)
Table S1 The cross-correlation values between the time series of
each cell subset, compared across each pair of treatment groups.
Two numbers are reported for each case: the cross-correlation
value, and the corresponding p-value, i.e. the probability of getting
this cross-correlation value by chance. P-values were computed
using the following non-parametric procedure: given a pair of time
series to be compared, 1,000 different random permutations were
generated from one of them, and the cross-correlation value was
then computed between the second series and each permutation.
The cross-correlation value computed for the original series was
then ranked with reference to these 1,000 values, yielding the
reported p-value.
Found at: doi:10.1371/journal.pone.0008447.s002 (0.03 MB
DOC)
Figure S1 The kinetics of CD4
+CD25
+Foxp3
+ cells expressed in
absolute cell numbers. Similar patterns to those determined by
FACS for percentages of cells were observable (compare to
Figure 2E in the text); however, additional noise was detectable in
measurements referring to absolute numbers of cells (see text). The
legend is the same as in Figure 2.
Found at: doi:10.1371/journal.pone.0008447.s003 (0.13 MB TIF)
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